Financial Review: TG Therapeutics (NASDAQ:TGTX) versus Affymax (OTCMKTS:AFFY)

TG Therapeutics (NASDAQ:TGTX) and Affymax (OTCMKTS:AFFY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Valuation and Earnings

This table compares TG Therapeutics and Affymax”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$264.79 million	19.12	$12.67 million	($0.10)	-325.30
Affymax	N/A	N/A	N/A	N/A	N/A

TG Therapeutics has higher revenue and earnings than Affymax.

Profitability

This table compares TG Therapeutics and Affymax’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	-5.42%	-8.32%	-3.40%
Affymax	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TG Therapeutics and Affymax, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	0	1	5	0	2.83
Affymax	0	0	0	0	0.00

TG Therapeutics currently has a consensus target price of $40.67, suggesting a potential upside of 25.01%. Given TG Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Affymax.

Institutional & Insider Ownership

58.6% of TG Therapeutics shares are held by institutional investors. 10.5% of TG Therapeutics shares are held by company insiders. Comparatively, 1.6% of Affymax shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

TG Therapeutics has a beta of 2.25, meaning that its stock price is 125% more volatile than the S&P 500. Comparatively, Affymax has a beta of 6.39, meaning that its stock price is 539% more volatile than the S&P 500.

Summary

TG Therapeutics beats Affymax on 6 of the 10 factors compared between the two stocks.

About TG Therapeutics

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.